Yujiro Maeoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yujiro Maeoka has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Akira Takahashi
Department of Nephrology, Hiroshima University Hospital , Hiroshima
8 shared publications- James A. McCormick
Oregon Health and Science University
7 shared publications Naoki Ishiuchi
Department of Nephrology, Hiroshima University Hospital , Hiroshima
7 shared publications- Takao Masaki
Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
7 shared publications - Xiao-Tong Su
Oregon Health and Science University
6 shared publications Yosuke Osaki
Department of Nephrology, Hiroshima University Hospital , Hiroshima
6 shared publications
Latest Publications
- 12 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy
Background: While proteinuria is a well-established surrogate marker in IgA nephropathy (IgAN), the independent prognostic value of early hematuria remission remains unclear. We hypothesized that treatment response at 6 months, particularly hematuria status, is associated with subsequent kidney outcomes. Methods: We conducted a single-center retrospective cohort study of biopsy-proven IgAN at Hiroshima University Hospital between April 2010 and March 2024. A 6-month landmark analysis was used to minimize immortal time bias, including patients who were event-free at 6 months, with follow-up starting at that time. Urinary red blood cell (uRBC) count at 6 months was used to classify patients into remission (<5 RBC/high-power field [HPF]), persistent moderate (5–29 RBC/HPF), and persistent severe (≥30 RBC/HPF). The primary outcome was a composite of end-stage kidney disease or a ≥30% decline in the estimated glomerular filtration rate. Multivariable Cox models, Kaplan–Meier analyses, and restricted cubic spline models were performed. Results: A total of 286 patients were analyzed (median age 43 years; 48.2% male). During a median follow-up of 3.1 years, 38 patients (13.3%) reached the composite outcome. Compared with remission, persistent severe hematuria was associated with higher risk of the outcome (hazard ratio 2.97, 95% confidence interval 1.33–6.67, P = 0.01). Restricted cubic spline analyses demonstrated a graded association between higher uRBC count and worse kidney outcomes. Conclusion: Persistent severe hematuria at 6 months was independently associated with worse kidney outcomes. Monitoring hematuria at 6 months may provide a clinically useful marker for risk stratification in patients with IgAN.
- 12 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy
Background: While proteinuria is a well-established surrogate marker in IgA nephropathy (IgAN), the independent prognostic value of early hematuria remission remains unclear. We hypothesized that treatment response at 6 months, particularly hematuria status, is associated with subsequent kidney outcomes. Methods: We conducted a single-center retrospective cohort study of biopsy-proven IgAN at Hiroshima University Hospital between April 2010 and March 2024. A 6-month landmark analysis was used to minimize immortal time bias, including patients who were event-free at 6 months, with follow-up starting at that time. Urinary red blood cell (uRBC) count at 6 months was used to classify patients into remission (<5 RBC/high-power field [HPF]), persistent moderate (5–29 RBC/HPF), and persistent severe (≥30 RBC/HPF). The primary outcome was a composite of end-stage kidney disease or a ≥30% decline in the estimated glomerular filtration rate. Multivariable Cox models, Kaplan–Meier analyses, and restricted cubic spline models were performed. Results: A total of 286 patients were analyzed (median age 43 years; 48.2% male). During a median follow-up of 3.1 years, 38 patients (13.3%) reached the composite outcome. Compared with remission, persistent severe hematuria was associated with higher risk of the outcome (hazard ratio 2.97, 95% confidence interval 1.33–6.67, P = 0.01). Restricted cubic spline analyses demonstrated a graded association between higher uRBC count and worse kidney outcomes. Conclusion: Persistent severe hematuria at 6 months was independently associated with worse kidney outcomes. Monitoring hematuria at 6 months may provide a clinically useful marker for risk stratification in patients with IgAN.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330 (4) , F422-F432
Kidney kallikrein-1 contributes to cleavage of γ-ENaC in vivo
Using a novel connecting tubule/cortical collecting duct specific kallikrein-1 knockout model, we show that γ- and α-ENaC cleavage is impaired by loss of renal kallikrein-1, without major disturbances in sodium or potassium handling. These findings highlight redundancy among ENaC regulatory pathways and suggest that proteolytic cleavage of ENaC, although useful as an indicator of ENaC-mediated transport under physiological conditions, may not, in and of itself, play a major role in ENaC function.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330 (4) , F422-F432
Kidney kallikrein-1 contributes to cleavage of γ-ENaC in vivo
Using a novel connecting tubule/cortical collecting duct specific kallikrein-1 knockout model, we show that γ- and α-ENaC cleavage is impaired by loss of renal kallikrein-1, without major disturbances in sodium or potassium handling. These findings highlight redundancy among ENaC regulatory pathways and suggest that proteolytic cleavage of ENaC, although useful as an indicator of ENaC-mediated transport under physiological conditions, may not, in and of itself, play a major role in ENaC function.
- Open Access
- 12 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Although C5 inhibitors, such as eculizumab and ravulizumab, have markedly improved outcomes, renal recovery remains limited in cases complicated by hypertensive emergency (HE) or malignant hypertension, likely due to complement-independent vascular injury. Angiotensin receptor–neprilysin inhibitor therapy exerts dual actions of renin–angiotensin system blockade and augmentation of natriuretic peptide signaling. Additionally, this therapy has recently demonstrated renal benefits in thrombotic microangiopathy with HE compared with conventional renin–angiotensin system inhibitors. However, the combined use of an angiotensin receptor–neprilysin inhibitor with a C5 inhibitor in aHUS with HE has not been reported. Case presentation: A 57-year-old Japanese man presented with marked anemia, severe renal dysfunction (serum creatinine concentration: 10.19 mg/dL; eGFR 5 mL/min/1.73 m 2 ), and hypertensive emergency (blood pressure: 198/102 mmHg). Laboratory examinations showed hemolytic anemia and thrombocytopenia, leading to a diagnosis of thrombotic microangiopathy. Plasma exchange was performed, and intravenous antihypertensive therapy was initiated on day 1. Ravulizumab was started on day 2 after thrombotic thrombocytopenic purpura and Shiga toxin-associated HUS were excluded, and aHUS was clinically suspected on the basis of isolated C3 hypocomplementemia. Despite the requirement for initial hemodialysis, renal function gradually improved, allowing withdrawal of dialysis by day 14. A renal biopsy showed thrombotic microangiopathy with intravascular thrombi and concentric arteriolar wall thickening resembling onion-skin lesions. Consequently, sacubitril/valsartan was initiated on day 23, resulting in further renal recovery (creatinine concentration: 3.79 mg/dL on day 22 to 1.23 mg/dL at 1 year; eGFR 14 to 48 mL/min/1.73 m 2 at 1 year) accompanied by improved blood pressure control. Genetic testing identified a heterozygous C3 c.493G > T (p.Val165Phe) variant, which confirmed C3 mutation-associated aHUS. Conclusions: We report the first case of C3 mutation-associated aHUS with HE, which was successfully treated with a combination of ravulizumab and sacubitril/valsartan. The renal improvement in this patient may suggest a potential, but unproven, contribution of angiotensin receptor–neprilysin inhibitor-based renin–angiotensin modulation to kidney recovery when added to complement inhibition in aHUS complicated by HE, although its independent effect remains unclear. Further cohort studies are warranted to clarify its potential therapeutic synergy.
- 12 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessC3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Although C5 inhibitors, such as eculizumab and ravulizumab, have markedly improved outcomes, renal recovery remains limited in cases complicated by hypertensive emergency (HE) or malignant hypertension, likely due to complement-independent vascular injury. Angiotensin receptor–neprilysin inhibitor therapy exerts dual actions of renin–angiotensin system blockade and augmentation of natriuretic peptide signaling. Additionally, this therapy has recently demonstrated renal benefits in thrombotic microangiopathy with HE compared with conventional renin–angiotensin system inhibitors. However, the combined use of an angiotensin receptor–neprilysin inhibitor with a C5 inhibitor in aHUS with HE has not been reported. Case presentation: A 57-year-old Japanese man presented with marked anemia, severe renal dysfunction (serum creatinine concentration: 10.19 mg/dL; eGFR 5 mL/min/1.73 m 2 ), and hypertensive emergency (blood pressure: 198/102 mmHg). Laboratory examinations showed hemolytic anemia and thrombocytopenia, leading to a diagnosis of thrombotic microangiopathy. Plasma exchange was performed, and intravenous antihypertensive therapy was initiated on day 1. Ravulizumab was started on day 2 after thrombotic thrombocytopenic purpura and Shiga toxin-associated HUS were excluded, and aHUS was clinically suspected on the basis of isolated C3 hypocomplementemia. Despite the requirement for initial hemodialysis, renal function gradually improved, allowing withdrawal of dialysis by day 14. A renal biopsy showed thrombotic microangiopathy with intravascular thrombi and concentric arteriolar wall thickening resembling onion-skin lesions. Consequently, sacubitril/valsartan was initiated on day 23, resulting in further renal recovery (creatinine concentration: 3.79 mg/dL on day 22 to 1.23 mg/dL at 1 year; eGFR 14 to 48 mL/min/1.73 m 2 at 1 year) accompanied by improved blood pressure control. Genetic testing identified a heterozygous C3 c.493G > T (p.Val165Phe) variant, which confirmed C3 mutation-associated aHUS. Conclusions: We report the first case of C3 mutation-associated aHUS with HE, which was successfully treated with a combination of ravulizumab and sacubitril/valsartan. The renal improvement in this patient may suggest a potential, but unproven, contribution of angiotensin receptor–neprilysin inhibitor-based renin–angiotensin modulation to kidney recovery when added to complement inhibition in aHUS complicated by HE, although its independent effect remains unclear. Further cohort studies are warranted to clarify its potential therapeutic synergy.
- Open Access
- 6 January 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (1) , 12
Relapsing peritoneal dialysis‑associated peritonitis caused by Pseudomonas oryzihabitans with concurrent tunnel infection: a case report and literature review
Peritoneal dialysis (PD)-associated peritonitis is linked to an increased risk of catheter removal and PD discontinuation, with these risks occurring more frequently in relapsing peritonitis than in primary peritonitis. Relapses are often attributed to persistent infection originating from the PD catheter, including tunnel infection (TI). Although Pseudomonas oryzihabitans is a commensal bacterium and recognized opportunistic pathogen, only a limited number of cases of P. oryzihabitans peritonitis—and none involving relapsing peritonitis with concurrent TI—have been reported. A 73-year-old Japanese man undergoing PD presented with abdominal pain, fatigue, fever, and decreased PD fluid drainage. He was diagnosed with PD-associated peritonitis caused by P. oryzihabitans , which was preceded by a persistent exit-site infection due to different organisms. A 21-day course of antimicrobial therapy combined with peritoneal lavage led to clinical improvement. However, 27 days after completing treatment, he developed relapsing peritonitis due to P. oryzihabitans , complicated by TI suspected on computed tomography. However, the patient declined catheter removal and chose outpatient intraperitoneal antibiotics. The relapse resolved, but persistent yellow drainage prompted cuff-shaving surgery. We present a case of peritonitis caused by P. oryzihabitans , initially presenting with exit site infection and later complicated by TI at recurrence, that was successfully treated without PD catheter removal. This case suggests that cuff-shaving combined with appropriate antimicrobial therapy may be an effective treatment option for P. oryzihabitans peritonitis when the peritonitis and catheter infection are not caused by the same organism.
- 6 January 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (1) , 12
Open AccessRelapsing peritoneal dialysis‑associated peritonitis caused by Pseudomonas oryzihabitans with concurrent tunnel infection: a case report and literature review
Peritoneal dialysis (PD)-associated peritonitis is linked to an increased risk of catheter removal and PD discontinuation, with these risks occurring more frequently in relapsing peritonitis than in primary peritonitis. Relapses are often attributed to persistent infection originating from the PD catheter, including tunnel infection (TI). Although Pseudomonas oryzihabitans is a commensal bacterium and recognized opportunistic pathogen, only a limited number of cases of P. oryzihabitans peritonitis—and none involving relapsing peritonitis with concurrent TI—have been reported. A 73-year-old Japanese man undergoing PD presented with abdominal pain, fatigue, fever, and decreased PD fluid drainage. He was diagnosed with PD-associated peritonitis caused by P. oryzihabitans , which was preceded by a persistent exit-site infection due to different organisms. A 21-day course of antimicrobial therapy combined with peritoneal lavage led to clinical improvement. However, 27 days after completing treatment, he developed relapsing peritonitis due to P. oryzihabitans , complicated by TI suspected on computed tomography. However, the patient declined catheter removal and chose outpatient intraperitoneal antibiotics. The relapse resolved, but persistent yellow drainage prompted cuff-shaving surgery. We present a case of peritonitis caused by P. oryzihabitans , initially presenting with exit site infection and later complicated by TI at recurrence, that was successfully treated without PD catheter removal. This case suggests that cuff-shaving combined with appropriate antimicrobial therapy may be an effective treatment option for P. oryzihabitans peritonitis when the peritonitis and catheter infection are not caused by the same organism.
- 25 October 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (22) , 7365-7382
Hypomagnesaemia‐associated hypokalaemia requires activation of both ENaC and ROMK
Hypokalaemia is common in hypomagnesaemic patients, but the in vivo mechanisms have not been determined. Along the distal nephron, lower intracellular Mg 2+ has been proposed to release the Mg 2+ ‐mediated inhibition of renal outer medullary K + (ROMK) channels, increasing urinary K + excretion. Higher activity of the epithelial Na + channel (ENaC), which provides the driving force for K + secretion via ROMK, may also be required. We tested the hypothesis that hypomagnesaemia‐induced hypokalaemia is associated with higher activities of both ENaC and ROMK. C57BL/6J mice were fed normal (NL), low Mg 2+ (LM), low Na + (LS) or low Na + /Mg 2+ (LS/LM) diets. Kidneys and blood were harvested for western blotting and measurement of plasma [K + ]. ROMK activity was measured by patch‐clamping of split‐open distal convoluted tubule 2 (DCT2)/connecting tubule (CNT) from mice on NL or LS/LM diets. Plasma [K + ] was significantly lower in mice on LS/LM diet. Compared with mice on NL diet, abundances of cleaved α‐ and γ‐ENaC, which correlate with ENaC activity, were higher in mice on LS diet, and lower in mice on LM diet but not on LS/LM diet, suggesting Na + and Mg 2+ restriction counteract each other. A lower natriuretic response to acute amiloride administration confirmed lower ENaC activity in mice on LM diet. ROMK activity along DCT2/CNT was higher in mice on LS/LM but not on LM diet compared with mice on NL diet. Together, our data suggest that Mg 2+ restriction inhibits ENaC activity, and both higher ENaC activity and disinhibition of ROMK are required for the development of hypokalaemia in the context of hypomagnesaemia. image Key points: In patch‐clamping experiments, lower intracellular Mg 2+ releases the Mg 2+ ‐mediated inhibition of renal outer medullary K + (ROMK) channels, increasing urinary K + excretion, but hypomagnesaemia does not always lead to hypokalaemia in several genetic disorders and animal experiments. Epithelial sodium channel (ENaC)‐mediated Na + entry provides the driving force for K + secretion via ROMK, but how hypomagnesaemia affects ENaC activity remains unknown. We found that ENaC activity is lower following dietary Mg 2+ restriction but is preserved with combined Mg 2+ /Na + restriction, stimulating K + secretion via ROMK. Our findings probably explain why Mg 2+ restriction alone cannot cause hypokalaemia in vivo and provide new insights into the mechanisms of hypomagnesaemia‐induced hypokalaemia.
- 25 October 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (22) , 7365-7382
Hypomagnesaemia‐associated hypokalaemia requires activation of both ENaC and ROMK
Hypokalaemia is common in hypomagnesaemic patients, but the in vivo mechanisms have not been determined. Along the distal nephron, lower intracellular Mg 2+ has been proposed to release the Mg 2+ ‐mediated inhibition of renal outer medullary K + (ROMK) channels, increasing urinary K + excretion. Higher activity of the epithelial Na + channel (ENaC), which provides the driving force for K + secretion via ROMK, may also be required. We tested the hypothesis that hypomagnesaemia‐induced hypokalaemia is associated with higher activities of both ENaC and ROMK. C57BL/6J mice were fed normal (NL), low Mg 2+ (LM), low Na + (LS) or low Na + /Mg 2+ (LS/LM) diets. Kidneys and blood were harvested for western blotting and measurement of plasma [K + ]. ROMK activity was measured by patch‐clamping of split‐open distal convoluted tubule 2 (DCT2)/connecting tubule (CNT) from mice on NL or LS/LM diets. Plasma [K + ] was significantly lower in mice on LS/LM diet. Compared with mice on NL diet, abundances of cleaved α‐ and γ‐ENaC, which correlate with ENaC activity, were higher in mice on LS diet, and lower in mice on LM diet but not on LS/LM diet, suggesting Na + and Mg 2+ restriction counteract each other. A lower natriuretic response to acute amiloride administration confirmed lower ENaC activity in mice on LM diet. ROMK activity along DCT2/CNT was higher in mice on LS/LM but not on LM diet compared with mice on NL diet. Together, our data suggest that Mg 2+ restriction inhibits ENaC activity, and both higher ENaC activity and disinhibition of ROMK are required for the development of hypokalaemia in the context of hypomagnesaemia. image Key points: In patch‐clamping experiments, lower intracellular Mg 2+ releases the Mg 2+ ‐mediated inhibition of renal outer medullary K + (ROMK) channels, increasing urinary K + excretion, but hypomagnesaemia does not always lead to hypokalaemia in several genetic disorders and animal experiments. Epithelial sodium channel (ENaC)‐mediated Na + entry provides the driving force for K + secretion via ROMK, but how hypomagnesaemia affects ENaC activity remains unknown. We found that ENaC activity is lower following dietary Mg 2+ restriction but is preserved with combined Mg 2+ /Na + restriction, stimulating K + secretion via ROMK. Our findings probably explain why Mg 2+ restriction alone cannot cause hypokalaemia in vivo and provide new insights into the mechanisms of hypomagnesaemia‐induced hypokalaemia.
- Open Access
- 29 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Abemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review
Background: Drug-induced acute interstitial nephritis (DI-AIN) is the most common type of AIN. DI-AIN occurs when medications trigger a T cell-mediated immune response that promotes tubulitis and interstitial inflammation with eosinophils, often resulting in acute kidney injury (AKI) with nephromegaly. Recently, prolonged use of cyclin-dependent kinase (CDK) 4/6 inhibitors, as oral molecular-targeted drugs for breast cancer, was identified as a cause of AKI, including AIN and acute tubular necrosis (ATN). To date, there have been no reported cases of AIN associated with the use of abemaciclib, a CDK4/6 inhibitor. Case presentation: A 66-year-old Japanese woman presented with persistent diarrhea and nausea shortly after the initiation of abemaciclib for breast cancer and was subsequently referred to our hospital with severe renal dysfunction (blood urea nitrogen, 128.7 mg/dL; creatinine, 15.16 mg/dL). Based on her elevated renal tubular damage markers and bilateral renal enlargement, acute renal failure was suspected. A renal biopsy revealed interstitial infiltration of mononuclear cells and eosinophils, along with tubulitis and epithelial cell damage within the renal tubules, suggesting AIN caused by abemaciclib. The renal function improved with glucocorticoid therapy following fluid replacement for pre-renal AKI, and the serum creatinine decreased to approximately 2 mg/dL within 2 months. Conclusions: We report a case of biopsy-proven AIN that developed shortly after the initiation of abemaciclib, leading to severe renal dysfunction with nephromegaly. While prolonged use of CDK4/6 inhibitors can cause both AIN and ATN, AIN can also occur after short-term use, highlighting the importance of a renal biopsy to determine the need for glucocorticoid therapy. Clinical trial number: Not applicable.
- 29 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Open AccessAbemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review
Background: Drug-induced acute interstitial nephritis (DI-AIN) is the most common type of AIN. DI-AIN occurs when medications trigger a T cell-mediated immune response that promotes tubulitis and interstitial inflammation with eosinophils, often resulting in acute kidney injury (AKI) with nephromegaly. Recently, prolonged use of cyclin-dependent kinase (CDK) 4/6 inhibitors, as oral molecular-targeted drugs for breast cancer, was identified as a cause of AKI, including AIN and acute tubular necrosis (ATN). To date, there have been no reported cases of AIN associated with the use of abemaciclib, a CDK4/6 inhibitor. Case presentation: A 66-year-old Japanese woman presented with persistent diarrhea and nausea shortly after the initiation of abemaciclib for breast cancer and was subsequently referred to our hospital with severe renal dysfunction (blood urea nitrogen, 128.7 mg/dL; creatinine, 15.16 mg/dL). Based on her elevated renal tubular damage markers and bilateral renal enlargement, acute renal failure was suspected. A renal biopsy revealed interstitial infiltration of mononuclear cells and eosinophils, along with tubulitis and epithelial cell damage within the renal tubules, suggesting AIN caused by abemaciclib. The renal function improved with glucocorticoid therapy following fluid replacement for pre-renal AKI, and the serum creatinine decreased to approximately 2 mg/dL within 2 months. Conclusions: We report a case of biopsy-proven AIN that developed shortly after the initiation of abemaciclib, leading to severe renal dysfunction with nephromegaly. While prolonged use of CDK4/6 inhibitors can cause both AIN and ATN, AIN can also occur after short-term use, highlighting the importance of a renal biopsy to determine the need for glucocorticoid therapy. Clinical trial number: Not applicable.
- Open Access
- 26 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-13
Early use of renin–angiotensin–aldosterone system inhibitors and stable renal function in familial focal segmental glomerulosclerosis with ACTN4 mutation: a case report and literature review
Background: Genetic mutations in alpha-actinin 4 (ACTN4) are one cause of familial focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (SRNS) in early adulthood, eventually progressing to end-stage kidney disease. Early initiation of renin–angiotensin–aldosterone system inhibitors (RAASis) is reported to delay progression of several forms of familial FSGS and SRNS; however, no cases involving ACTN4 mutations have been reported. Case presentation: A 16-year-old boy was admitted to our hospital for a detailed evaluation of proteinuria that first appeared during treatment for Duchenne muscular dystrophy (DMD) and persisted for 1 year. He had been treated with prednisolone and an angiotensin-converting enzyme inhibitor (ACEi) for 2 years prior to the onset of persistent proteinuria. A renal biopsy revealed segmental sclerosis in 1 of 40 glomeruli, with effaced foot processes observed under electron microscopy. Genetic testing identified ACTN4 mutation (c·776C > T, p.T259I), leading to a diagnosis of autosomal dominant FSGS caused by ACTN4 mutation. After the first appearance of proteinuria, the patient’s renal function and urinary protein levels remained stable for following 7 years. Conclusions: We report a case of adolescent-onset FSGS with ACTN4 mutation diagnosed during ACEi therapy for the prevention of DMD-associated cardiomyopathy. The patient exhibited stable renal function and no disease progression compared with his father and previously reported cases with the same variant. This is the first reported case of early RAASi induction for treating ACTN4-associated FSGS with long-term stable renal function.
- 26 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-13
Open AccessEarly use of renin–angiotensin–aldosterone system inhibitors and stable renal function in familial focal segmental glomerulosclerosis with ACTN4 mutation: a case report and literature review
Background: Genetic mutations in alpha-actinin 4 (ACTN4) are one cause of familial focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (SRNS) in early adulthood, eventually progressing to end-stage kidney disease. Early initiation of renin–angiotensin–aldosterone system inhibitors (RAASis) is reported to delay progression of several forms of familial FSGS and SRNS; however, no cases involving ACTN4 mutations have been reported. Case presentation: A 16-year-old boy was admitted to our hospital for a detailed evaluation of proteinuria that first appeared during treatment for Duchenne muscular dystrophy (DMD) and persisted for 1 year. He had been treated with prednisolone and an angiotensin-converting enzyme inhibitor (ACEi) for 2 years prior to the onset of persistent proteinuria. A renal biopsy revealed segmental sclerosis in 1 of 40 glomeruli, with effaced foot processes observed under electron microscopy. Genetic testing identified ACTN4 mutation (c·776C > T, p.T259I), leading to a diagnosis of autosomal dominant FSGS caused by ACTN4 mutation. After the first appearance of proteinuria, the patient’s renal function and urinary protein levels remained stable for following 7 years. Conclusions: We report a case of adolescent-onset FSGS with ACTN4 mutation diagnosed during ACEi therapy for the prevention of DMD-associated cardiomyopathy. The patient exhibited stable renal function and no disease progression compared with his father and previously reported cases with the same variant. This is the first reported case of early RAASi induction for treating ACTN4-associated FSGS with long-term stable renal function.
- Open Access
- 13 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Peritoneal dialysis-associated polymicrobial peritonitis with slow onset after root canal treatment: the first case and review of the literature
Peritoneal dialysis (PD)-associated peritonitis is linked to an increased risk of mortality and catheter removal, with a higher incidence of these risks observed in polymicrobial peritonitis compared with single-organism infection. In PD patients, invasive procedures can cause peritonitis, typically within 7 days, through transient bacteremia. Although dental procedures are widely recognized as a cause of transient bacteremia, only a limited number of cases involving PD-associated peritonitis after dental procedures, and no cases of polymicrobial peritonitis, have been reported. A 60-year-old man undergoing PD presented with acute low abdominal pain, and was diagnosed with PD-associated peritonitis caused by Streptococcus (S.) oralis, S. vestibularis, and S. salivarius. The polymicrobial peritonitis was successfully treated with antibiotics and catheter removal was not required. Medical consultation after admission revealed a history of root canal treatment for dental caries in the right maxillary second molar, and a dental examination during hospitalization confirmed its success. We report a case of PD-associated peritonitis caused by co-infection with three species of viridans group streptococci, which developed 9 days after the completion of root canal treatment. This case history suggests that it may be important to carefully observe patients until 10 days after dental procedures, because of the slow onset of peritonitis following such procedures.
- 13 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Open AccessPeritoneal dialysis-associated polymicrobial peritonitis with slow onset after root canal treatment: the first case and review of the literature
Peritoneal dialysis (PD)-associated peritonitis is linked to an increased risk of mortality and catheter removal, with a higher incidence of these risks observed in polymicrobial peritonitis compared with single-organism infection. In PD patients, invasive procedures can cause peritonitis, typically within 7 days, through transient bacteremia. Although dental procedures are widely recognized as a cause of transient bacteremia, only a limited number of cases involving PD-associated peritonitis after dental procedures, and no cases of polymicrobial peritonitis, have been reported. A 60-year-old man undergoing PD presented with acute low abdominal pain, and was diagnosed with PD-associated peritonitis caused by Streptococcus (S.) oralis, S. vestibularis, and S. salivarius. The polymicrobial peritonitis was successfully treated with antibiotics and catheter removal was not required. Medical consultation after admission revealed a history of root canal treatment for dental caries in the right maxillary second molar, and a dental examination during hospitalization confirmed its success. We report a case of PD-associated peritonitis caused by co-infection with three species of viridans group streptococci, which developed 9 days after the completion of root canal treatment. This case history suggests that it may be important to carefully observe patients until 10 days after dental procedures, because of the slow onset of peritonitis following such procedures.
- Open Access
- 6 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Polycythemia secondary to bilaterally enlarged kidneys in T-Cell acute lymphoblastic leukemia: a case report and literature review
Polycythemia is a rare disease that can cause hypertension. Secondary polycythemia with increased production of erythropoietin (EPO) is associated with several kidney diseases, including hydronephrosis and cystic disease. However, there have been no reports of a case presenting with polycythemia secondary to bilateral nephromegaly caused by renal infiltration of T-cell acute lymphoblastic leukemia (T-ALL). A 32-year-old Japanese man presented with marked hypertension (215/150 mmHg) with renal insufficiency (creatinine 3.7 mg/dL), proteinuria, hematuria, bilateral nephromegaly, polycythemia (hemoglobin 20.2 g/dL), and increased serum EPO (38.7 mIU/mL, range 4.2–23.7 mIU/mL). Based on renal and bone marrow biopsy findings, he was diagnosed with T-ALL and bilaterally enlarged kidneys caused by renal infiltration of leukemic cells. There was no evidence of endocrine hypertension or fluid retention. Remission induction chemotherapy led to a decrease in kidney size, hemoglobin levels, and serum EPO levels, and allowed dose reductions of most hypertensive drugs, suggesting that hypertension was secondary to polycythemia. The patient’s renal function gradually improved and hemodialysis was discontinued after 1 month of chemotherapy. We report a case of marked hypertension and secondary polycythemia induced by severe renal infiltration of T-ALL at diagnosis, which were synchronically improved with induction chemotherapy. This case history suggests the importance of considering lymphoproliferative diseases in the differential diagnosis of secondary polycythemia, leading to severe hypertension.
- 6 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Open AccessPolycythemia secondary to bilaterally enlarged kidneys in T-Cell acute lymphoblastic leukemia: a case report and literature review
Polycythemia is a rare disease that can cause hypertension. Secondary polycythemia with increased production of erythropoietin (EPO) is associated with several kidney diseases, including hydronephrosis and cystic disease. However, there have been no reports of a case presenting with polycythemia secondary to bilateral nephromegaly caused by renal infiltration of T-cell acute lymphoblastic leukemia (T-ALL). A 32-year-old Japanese man presented with marked hypertension (215/150 mmHg) with renal insufficiency (creatinine 3.7 mg/dL), proteinuria, hematuria, bilateral nephromegaly, polycythemia (hemoglobin 20.2 g/dL), and increased serum EPO (38.7 mIU/mL, range 4.2–23.7 mIU/mL). Based on renal and bone marrow biopsy findings, he was diagnosed with T-ALL and bilaterally enlarged kidneys caused by renal infiltration of leukemic cells. There was no evidence of endocrine hypertension or fluid retention. Remission induction chemotherapy led to a decrease in kidney size, hemoglobin levels, and serum EPO levels, and allowed dose reductions of most hypertensive drugs, suggesting that hypertension was secondary to polycythemia. The patient’s renal function gradually improved and hemodialysis was discontinued after 1 month of chemotherapy. We report a case of marked hypertension and secondary polycythemia induced by severe renal infiltration of T-ALL at diagnosis, which were synchronically improved with induction chemotherapy. This case history suggests the importance of considering lymphoproliferative diseases in the differential diagnosis of secondary polycythemia, leading to severe hypertension.
- 24 January 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Effect of haemodiafiltration versus haemodialysis on vascular access patency when starting haemodialysis
Background: Haemodiafiltration (HDF) therapy improves the prognosis by reducing inflammation and oxidative stress and improving endothelial function. These factors contribute to vascular access (VA) stenosis, one of the most common complications in patients on haemodialysis (HD) or HDF. This study aimed to assess the efficacy of HDF on VA patency. Methods: This multicentre, prospective, observational study with post hoc analysis included 612 patients among 643 who underwent VA procedures and started dialysis between April 2012 and March 2021. A total of 516 patients were on HD since starting dialysis, while 96 switched to HDF after starting dialysis. One-to-one propensity score matching was performed to compare the 24-month patency rates of VA between groups by Kaplan–Meier and logrank tests, and a Cox proportional hazards regression analysis was used to identify factors affecting patency rates. Results: There were 87 patients in each group. The 24-month primary patency rates were 74.2% for HDF and 47.7% for HD (P < .001). A multivariate Cox proportional hazards analysis showed that a history of cardiovascular disease {hazard ratio [HR] 2.29 [95% confidence interval (CI) 1.21–4.34], P = .01} and higher haemoglobin A1c values [HR 1.37 (95% CI 1.00–1.82), P = .04] were associated with poor 24-month primary patency. However, HDF [HR 0.30 (95% CI 0.16–0.56), P < .001] and use of statins [HR 0.50 (95% CI 0.27–0.94), P = .03] were associated with better patency. A stratified analysis showed that HRs for loss of VA patency were lower in patients with HDF than in those with HD in the subgroups of ≥65 years, male sex, radiocephalic arteriovenous fistula, a history of diabetes mellitus or cardiovascular disease, haemoglobin concentrations <10 g/dl and albumin concentrations <3.5 g/dl. Conclusions: HDF potentially improves VA patency rates compared with HD, even in patients with cardiovascular disease or diabetes, commonly associated with poor patency.
- 24 January 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Effect of haemodiafiltration versus haemodialysis on vascular access patency when starting haemodialysis
Background: Haemodiafiltration (HDF) therapy improves the prognosis by reducing inflammation and oxidative stress and improving endothelial function. These factors contribute to vascular access (VA) stenosis, one of the most common complications in patients on haemodialysis (HD) or HDF. This study aimed to assess the efficacy of HDF on VA patency. Methods: This multicentre, prospective, observational study with post hoc analysis included 612 patients among 643 who underwent VA procedures and started dialysis between April 2012 and March 2021. A total of 516 patients were on HD since starting dialysis, while 96 switched to HDF after starting dialysis. One-to-one propensity score matching was performed to compare the 24-month patency rates of VA between groups by Kaplan–Meier and logrank tests, and a Cox proportional hazards regression analysis was used to identify factors affecting patency rates. Results: There were 87 patients in each group. The 24-month primary patency rates were 74.2% for HDF and 47.7% for HD (P < .001). A multivariate Cox proportional hazards analysis showed that a history of cardiovascular disease {hazard ratio [HR] 2.29 [95% confidence interval (CI) 1.21–4.34], P = .01} and higher haemoglobin A1c values [HR 1.37 (95% CI 1.00–1.82), P = .04] were associated with poor 24-month primary patency. However, HDF [HR 0.30 (95% CI 0.16–0.56), P < .001] and use of statins [HR 0.50 (95% CI 0.27–0.94), P = .03] were associated with better patency. A stratified analysis showed that HRs for loss of VA patency were lower in patients with HDF than in those with HD in the subgroups of ≥65 years, male sex, radiocephalic arteriovenous fistula, a history of diabetes mellitus or cardiovascular disease, haemoglobin concentrations <10 g/dl and albumin concentrations <3.5 g/dl. Conclusions: HDF potentially improves VA patency rates compared with HD, even in patients with cardiovascular disease or diabetes, commonly associated with poor patency.